论文信息 - Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer* - 字舞流文

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*

D. Lacombe | C. Punt | X. Paoletti | F. Caponigro | P. Fumoleau | V. Diéras | P. Kerbrat | C. Dittrich | R. Sorio | C. de Balincourt